Avalere experts explore how potential implications of the Inflation Reduction Act (IRA)’s out-of-pocket cap, in addition to other key regulatory and policy activities shaping benefit design and patient cost-share (e.g., EHB), could impact patient commercial and foundation assistance.
In this video, Avalere market access experts discuss major takeaways from the 2024 NCCN (National Comprehensive Cancer Network) Annual Conference in the areas of reimbursement, early detection of cancer, consideration of a broader pool as provider decision makers, and patient involvement in their care decisions.
Ahead of Asembia 2024, Avalere market access experts discuss the potential impacts of IRA provisions, including Part D redesign and Medicare drug price negotiation, on go-to-market and contracting strategy.
Ahead of the upcoming Asembia and ISPOR conferences, Avalere experts discuss the role of external assessors in value assessment.
This expert panel will address the challenge of integrating patient perspectives into value assessments, discussing implications for evidence strategy, health equity, caregiver involvement, and downstream impacts on care delivery.
Avalere experts provide insights on the dynamics and policy proposals surrounding recent drug shortages.
Ahead of Asembia 2024, Avalere experts discuss the evolution of biopharmaceutical value requirements and how organizations will need to evolve their business models accordingly.
Plans adapt to market changes in risk adjustment coding. Interviews with plan professionals reveal three trends for efficiency, effectiveness, and compliance.
If CMS lowers the dual-eligible enrollment threshold it uses to define D-SNP look-alikes, the demographics in look-alike plan enrollment will likely change.
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts summarize key learnings for pharmaceutical companies to consider.
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts explore policies shaping rare disease drug development and access.
Continued emphasis on diabetes management technology and patient-centered care in updated clinical management standards highlight the importance of advancing quality measurement.
Rates of filled prescriptions for nebulizers in Medicare FFS vary across factors such as age, disability, and race/ethnicity.
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into access drivers and considerations in the rare disease space.
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into patient centricity trends in rare disease.
Join Avalere’s healthcare policy experts as they dissect the Advance Notice of Methodological Changes for CY 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies and discuss the future trajectory of Medicare Advantage (MA) in Part D and potential outcomes, headwinds, and tailwinds for health plans.
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts provide an introduction into regulatory approaches to rare diseases.
Recent FDA authorization of Florida’s Section 804 Importation Program has prompted increased focus on importation pathways.
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #10: Quantifying Indirect Burden and Measuring Novel Elements of Value
Avalere experts are joined by Kevin L. Hagan, President of the PAN Foundation, to discuss their findings on the impacts of the Inflation Reduction Act’s Part D benefit redesign on patient utilization and affordability.
